Pegylated Interferon Alfa, Nitazoxanide, Telapravir and Ribavirin in prior experienced chronic hepatitis C Genotype 1 patients - A randomized Placebo control clinical Pilot Trial (INTRIGUE-C)

被引：0
|
作者：
Basu, Patrick [1 ,2 ]
Shah, Niraj J. [3 ]
Farhat, Sakina [2 ]
Mittimani, Kavya [2 ]
Siriki, Ravi [2 ]
Rahman, Md A. [2 ]
Ang, Lynn P. [2 ]
Win, S. [2 ]
Brown, Robert S. [1 ]
机构：
[1] Columbia Univ, Sch Phys & Surg, New York, NY USA
[2] N Shore Forest Hills Hosp, Hofstra Med Sch NY, New York, NY USA
[3] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA
来源：
HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1806
引用
收藏
页码：1035A / 1035A
页数：1
相关论文
共 50 条
  • [21] Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents: A pilot study
    Hasan, Fuad
    Alsarraf, Khalid
    Qabandi, Wafa
    GASTROENTEROLOGY, 2006, 130 (04) : A840 - A840
  • [22] Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C
    S. K. Tohra
    S. Taneja
    S. Ghosh
    B. K. Sharma
    A. Duseja
    R. K. Dhiman
    A. Das
    Y. K. Chawla
    Digestive Diseases and Sciences, 2011, 56
  • [23] Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C
    Tohra, S. K.
    Taneja, S.
    Ghosh, S.
    Sharma, B. K.
    Duseja, A.
    Dhiman, R. K.
    Das, A.
    Chawla, Y. K.
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (08) : 2449 - 2455
  • [24] Randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4
    Rossignol, J. F.
    Elfert, A.
    El-Gohary, Y.
    Keeffe, E. B.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S30 - S30
  • [25] Pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a or alfa-2b with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C
    Di Bisceglie, AM
    Rustgi, VK
    Thuluvath, P
    Davis, M
    Ghalib, R
    Lyons, MF
    Ondovik, MS
    Lopez-Talavera, JC
    HEPATOLOGY, 2004, 40 (04) : 734A - 734A
  • [26] Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection
    Nishiguchi, Shuhei
    Sakai, Yoshiyuki
    Kuboki, Makoto
    Tsunematsu, Satoshi
    Urano, Yasuhisa
    Sakamoto, Wataru
    Tsuda, Yasuhiro
    Steinmann, Gerhard
    Omata, Masao
    LIVER INTERNATIONAL, 2014, 34 (01) : 78 - 88
  • [27] Effects of High Dose Ribavirin, Alinia® (Nitazoxanide) and Pegylated Interferon alfa-2a in Attaining Sustained Viral Response in Treatment of Chronic Hepatitis C (ERAIS-C trial) - Interim Results in Naive Genotype 1 Patients
    Basu, P. Patrick
    Rayapudi, Krishna
    Pacana, Tommy
    Shah, Niraj James
    Brown, Robert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S125 - S125
  • [28] Simeprevir in combination with pegylated interferon-α and ribavirin in the treatment of naive patients with genotype 1 chronic hepatitis C
    Burnevich, E. Z.
    TERAPEVTICHESKII ARKHIV, 2014, 86 (11): : 105 - 114
  • [29] Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C
    van Leusen, Robert
    Adang, Rob P. R.
    de Vries, Richard A.
    Cnossen, Trijntje T.
    Konings, Constantijn J. A. M.
    Schalm, Solko W.
    Tan, Adriaan C. I. T. L.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (02) : 721 - 725
  • [30] A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C
    Pham Thi Thu Thuy
    Bunchorntavakul, Chalermrat
    Ho Tan Dat
    Reddy, K. Rajender
    JOURNAL OF HEPATOLOGY, 2012, 56 (05) : 1012 - 1018
12345